ge biopharma acquisit lead growth futur
maintain buy rate maintain tp
estim tp base forward
price-to-earnings multipl ep expect
price/ sale give upsid potenti
upsid potenti reduc due increas
stock price estim top line revenu growth
due acquisit
expect provid addit sale earn
growth opportun dhr life scienc segment
estim base follow factor strong
growth revenu double-digit growth china
new product launch strateg acquisit
sale grew core
revenu growth acquisit increas revenu
impact foreign currenc translat decreas
revenu quarter
geograph high growth market grew high single-digit
led double-digit growth china develop market
mid single-digit growth low single-digit
growth western europ
excit acquisit
continu expect deal close busi
excel complement current biolog
workflow solut bring highli innov industri
lead product suit life scienc portfolio
compani name corp tickerdhrstock ratingbuyunchangedindustri viewoverweightpositivepric jun week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth corp june
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu life scienc segment increas
sale led
strong sale growth high-growth market
total revenu diagnost segment increas
sale segment
clinic lab busi increas y/i basi
due increas demand high-growth market led
china north america
total sale environment appli solut segment
increas sale
segment water qualiti busi increas high-singl
digit rate quarter
expect ep rang
non-gaap adjust ep expect
rang revis done mainli
adjust dilut caus offer
common share fund acquisit biopharma
current price-to-earnings multipl
due increas stock price
averag price-to-earnings price-to-earnings
grown past due strong perform
compani expect forward price-to-earnings multipl
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jul ex-dividend date jun last split factor new per last split date jul inform danah corp june
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research develop sell gener administr sg oper interest incom interest incom incom incom minor net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli corp june
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item danah corp june
oper cash flow decreas compar
due lower earn higher cash use fund trade account receiv inventori
net cash use invest activ compar
increas due cash use acquisit busi invest non-market
equiti secur quarter
net cash provid financ activ compar net cash use
financ activ increas due public offer common
prefer stock lower net repay commerci paper borrow
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu debt- issuanc capit repurchas capit stock- payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end corp june
danah deliv strong revenu growth oper margin expans
lead double-digit adjust ep free cash flow growth
total revenu increas compar
sale grew core basi acquisit
increas revenu impact foreign currenc translat
decreas revenu
geograph high growth market grew high single-digit led double-digit
growth china across develop market saw mid single-digit
growth low single-digit growth western europ
cog increas compar
increas due impact higher y/i sale volum
includ sale recent acquir busi partli off-set increment
y/i cost save associ restructur continu product
improv action taken
gross profit increas compar
gross margin compar
gross margin decreas due impact product mix higher
freight tariff cost partial off-set impact higher y/i sale
volum includ sale recent acquir busi increas leverag
certain manufactur cost increment y/i cost save associ
restructur activ continu product improv action
taken
sg expens increas compar
sg expens sale
compar increas driven invest
sale market growth initi provis legal matter
partial off-set benefit increas leverag dhr gener
administr cost base result higher sale volum
compar
increas
compar
 expens increas compar
 expens sale constant
y/i increas dhr new product develop initi
correspond increas sale
compar
oper profit increas compar
oper margin increas bp despit
meaning foreign currenc headwind stronger dollar y/i exclud
foreign currenc impact core oper margin would
net earn declin
compar
incom net compar
interest expens compar
decreas due impact dhr cross-curr swap
deriv interest incom compar
effect tax rate compar
effect tax rate differ feder statutori rate
princip due impact net discret tax charg
per dilut share relat chang estim associ prior period
uncertain tax posit audit settlement net releas valuat
allow associ certain foreign tax credit tax benefit result
chang tax law excess tax benefit stock-bas
net earn declin compar
ep decreas
compar non-gaap ep increas
compar
danah report segment includ life scienc diagnost dental
total revenu life scienc segment increas
compar price increas
segment contribut sale growth y/i basi
reflect compon core revenu growth
oper profit increas compar
oper margin increas compar
sale led strong sale growth high-growth market
western europ partial off-set lower core sale clinic end-market
north america due difficult prior year comparison
growth led demand academ pharmaceut end-
market servic offer sale microscopi product grew
partial driven recent new product releas led
north america china
demand busi flow cytometri particl count product
line increas across major geographi led north america china
western europ
sale filtrat separ purif technolog increas
across major geographi led growth
biopharmaceut aerospac fluid technolog process
sale growth acquisit due acquisit integr dna
technolog april provid addit sale earn growth
opportun segment expand segment product line
divers includ new product servic offer area genom
consum idt revenu grew y/i basi growth across major
product line major geographi driven north america
revenu increas
compar
sale filtrat
separ
increas across
major geographi
led growth
biopharmaceut
aerospac fluid
technolog process
industri end-
revenu increas
compar
sale
busi increas
y/i basi due
increas demand
high-growth
market led china
north america
ge biopharma acquisit expect complet subject
customari condit includ receipt applic regulatori approv
upon close expect includ ge biopharma busi within
ge biopharma acquisit expect provid addit sale
earn growth opportun dhr life scienc segment expand
busi geograph product line divers includ new product
servic offer area process chromatographi consum cell
cultur media single-us technolog develop instrument
consum complement dhr current biolog workflow solut
total revenu diagnost segment increas
compar price segment
significantli impact sale growth year-over-year basi
oper profit declin compar
oper margin declin
compar decreas due increment y/i
cost associ variou new product develop sale servic
market growth invest unfavor product mix impact
foreign currenc exchang rate net higher core sale
volum increment y/i cost save associ restructur
action continu product improv initi taken
sale segment clinic lab busi increas y/i basi
due increas demand high-growth market led china
north america partial off-set lower demand western europ
immunoassay autom product line drove core sale growth
sale decreas slightli molecular diagnost busi growth
develop market off-set difficult prior year sale
comparison driven sever flu season
sale acut care diagnost busi increas y/i
instal base growth drove continu strong sale blood ga
immunoassay product line across major geographi led china
sale patholog diagnost busi grew year-over-year
three-month period demand advanc stain core
histolog product line increas core sale north america china
decreas
compar
revenu growth
specialti
led high-growth
north america
total revenu dental segment decreas
compar price segment
neg impact sale growth y/i basi
reflect compon core revenu growth
oper profit decreas compar
oper margin declin
compar
oper profit declin due lower overal price increment y/i cost
associ sale market growth invest net higher
core sale volum lower spend product initi cost
save associ product initi taken impact
foreign currenc exchang rate bp
revenu growth specialti consum busi consist
implant system orthodont product led high-growth
market primarili china north america sale growth
driven demand premium implant system equip well
increas demand orthodont product due partial recent product
sale dental equip tradit dental consum grew
led demand high-growth market sale also grew
north america busi experienc stabil market
realign certain distribut relationship disrupt perform
juli announc intent spin-off dental busi
separ publicly-trad compani februari connect
announc ge biopharma acquisit also announc
modif plan respect dental busi specif
intend conduct initi public offer share dental
busi second half subject satisfact certain
condit includ obtain final approv danah board
director favor rule ir regulatori approv
total sale environment appli solut segment increas
compar price increas
segment contribut sale growth y/i basi quarter
reflect compon core revenu growth
oper profit increas compar
oper margin compar
sale segment water qualiti busi increas high-singl
digit rate quarter y/i core sale analyt
instrument product line grew driven increas
demand high-growth market particularli china western europ
revenu growth busi chemic treatment solut product line
driven higher demand oil ga primari metal
chemic end-market partial off-set lower core sale power end-
revenu increas
compar
increas
compar
geograph y/i core revenu growth chemic treatment solut
driven increas demand north america sale busi
ultraviolet water disinfect product line increas across major end-
market quarter led complet sever municip project
geograph y/i core sale growth ultraviolet water disinfect product
driven north america china
sale segment product identif busi increas
low-singl digit rate quarter increas demand mark
code equip relat consum drove core sale growth
north america western europ high-growth market
packag color solut product servic increas demand
packag off-set lower demand color solut
geograph year-over-year core revenu growth packag color
solut product servic strengthen high-growth market
off-set soft develop market
revenu growth
solut driven
increas demand
sale
increas low-singl
digit rate
sciencesdiagnosticsdentalenvironment appli solut expect ep
rang
non-gaap
adjust ep expect
rang
revis done
mainli adjust
dilut caus
danah offer
common share fund
acquisit
guidanc conclus
expect ep rang non-gaap
adjust ep expect rang
revis done mainli adjust dilut caus offer
common share fund acquisit biopharma busi
expect ep adjust ep
rang
danah net sale increas organ sale
quarter grew acquir asset posit impact
growth howev foreign currenc translat neg impact
quarter expect acquisit close
complement biolog workflow solut
total revenu life scienc segment increas
growth driven gain acquir asset
growth core sale partial off-set advers impact foreign currenc
total revenu diagnost segment increas
growth due increas core sale partial off-set
neg impact foreign currenc translat
total revenu dental segment declin
core sale growth off-set advers impact
unfavor movement foreign currenc intend spin-off
dental segment independ publicly-trad compani dentalco
total revenu environment appli solut increas
growth due increas core sale
posit impact acquir asset howev foreign currenc translat
advers impact quarter
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin ttm basi compar
oper margin decreas ttm basi compar
net margin declin ttm basi compar
y/i revenu growth ttm basi compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth corp june
mrqgross mrqcog mrqoper mrqnet mrqr mrqsg sale danah corp june
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth mrqfinanci mrqreturn mrqreturn asset danah corp june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item danah corp june
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free corp june
current price-to-earnings multipl due increas stock
price averag price-to-earnings price-to-earnings grown past due strong
perform compani expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc price row associ fmr wellington manag compani massachusett servic morgan america northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard price row capit appreci vanguard specialized-dividend growth spdr etf mf seri trust i-mf valu vanguard institut fund-institut price row chip growth fund fidel contrafund fidel competit
developmentsdanah announc offer common stock mandatori convert prefer stockfebruari corpor announc commenc concurr offer share common stock share seri mandatori convert prefer stock subject market condit offer expect grant underwrit separ option purchas share common stock share mandatori convert prefer stock danah acquir biopharma busi gener electr life scienc billionfebruari corpor announc enter definit agreement compani acquir biopharma busi ge biopharma cash purchas price given anticip tax benefit transact structur net purchas price repres multipl time expect ebitda ge biopharma danah announc spin dental busi independ publicli trade companyjun corpor announc intent spin dental segment independ publicly-trad compani dentalco transact intend tax-fre sharehold expect complet second half believ dental busi effect stand-alone compani greater focu around organ inorgan invest opportun corp june
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
roa roi roe ttm
basi stood
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit corp june
consensu view analyst trend stock
rate expect
compar
 growth
rate
dhr forward price-to-earnings
higher
annual usdgrowth high day day day estim avgfive-year growth forecast comparisondhrindustri avg avgprice/earn yield corp june
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr next
qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate corp june
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price volatil period dip april
reduc guidanc
stock gave return period averag volum share trade
stock price volatil show upward trend surg april
stock gave return past one year rang stock
stock price shown upward trend past surg may
stock given total return last year due strong growth busi
danah deliv strong perform quarter growth revenu
increas adjust ep recommend buy rate tp
base recent acquisit continu strong perform quarter
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
